Evidence map›Paper›PMID 39497118›Full record

ArticleBMC endocrine disorders2024

Increased risk of vascular complications in patients with type 2 diabetes and fatty liver disease.

Weixia Sun, Dechen Liu, Ting Yang, Ziwei Zhou, Dan Li, Zhuoxiao Zhao, Xuan Zhang, Liyun Wang, Ling Li

Abstract read
In one paragraph

Article in BMC endocrine disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weixia Sun *Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
Dechen Liu *Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
Ting Yang *Department of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
Ziwei ZhouDepartment of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China.
Dan LiKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd., Hangzhou, 310007, China.
Zhuoxiao ZhaoNanjing Gaochun Hospital of Traditional Chinese Medicine, Nanjing, 211300, China.
Xuan ZhangKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd., Hangzhou, 310007, China.
Liyun WangThe Affiliated Yixing Hospital of Jiangsu University, Yixing, 214200, China. staff532@yxph.com.
Ling LiDepartment of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, 210009, China. dr_liling@126.com.

Funding

Medical Key Discipline of Jiangsu Province ZDXK202203Natural Science Foundation of China 82320108003,82170845, 82000740the Open Project of Key Laboratory of Environmental Medicine Engineering of Ministry of Education 2024EME001
6 · The paper itself

Abstract

backgroundThe prevalence of steatotic liver disease (SLD) in patients with type 2 diabetes (T2DM) exceeds 50%. This study aimed to investigate the clinical characteristics of SLD and liver fibrosis in Chinese patients with T2DM.

methodsInpatients from 2021 to 2023 were included in the study. Fatty liver index (FLI) and fibrosis-4 (FIB-4) were calculated to assess hepatic steatosis and fibrosis respectively. Statistical analysis was completed by SPSS v25 and GraphPad Prism v8.0.1.

resultsOf the 1466 participants, about one-third of the patients in T2DM-SLD group were diagnosed with liver fibrosis (LF), and the percentage of patients over 50 years old was 85.9%. Patients with SLD had higher levels of BMI, blood pressure, liver enzymes, fasting blood glucose (FBG), HbA1c, C-peptide, total cholesterol (TC) and triglyceride (TG) (P<0.05 for all). Patients with liver fibrosis had lower TC, TG, hemoglobin (Hb), erythrocyte count (RBC), leukocyte count (WBC) and platelet (PLT) levels (P<0.05 for all). Compared with simple T2DM and SLD-NLF (non-liver fibrosis) groups, for patients over 50 years old, the prevalence of coronary heart disease, stroke, tumor, and diabetic nephropathy was higher in patients with liver fibrosis. Liver fibrosis might be the risk factor of arterial stiffness, stroke, coronary heart disease and numbness based on multivariable logistic regression analysis.

conclusionHepatic steatosis and fibrosis were common in patients with T2DM. Liver fibrosis was relevant to many macrovascular and microvascular diabetic complications.

Indexed as

Diabetes Mellitus, Type 2Liver CirrhosisAdultAgedChinaFatty LiverFemaleFollow-Up StudiesHumansMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePrevalencePrognosisRisk FactorsLiver fibrosisLiver steatosisType 2 diabetes

Identifiers

PMID39497118
PMCPMC11536858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.